{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T21:00:37Z","timestamp":1794690037776,"version":"4.9.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2009736"],"award-info":[{"award-number":["APP2009736"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2007007"],"award-info":[{"award-number":["APP2007007"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009725","name":"Sunshine Coast Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijantimicag.2026.107883","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:56:07Z","timestamp":1781308567000},"page":"107883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prospective evaluation of therapeutic target attainment with a beta-lactam dosing nomogram in critically ill adult patients"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-4456","authenticated-orcid":false,"given":"Paul","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menino Osbert","family":"Cotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd H.","family":"Abdul-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Wilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Beall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ijantimicag.2026.107883_bib0001","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in Intensive Care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ijantimicag.2026.107883_bib0002","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u00df-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ijantimicag.2026.107883_bib0003","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00134-013-3187-2","article-title":"Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial","volume":"40","author":"De Waele","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2026.107883_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01008-18","article-title":"Pharmacodynamic target attainment for cefepime, meropenem and piperacillin\/tazobactam using a pharmacokinetic\/pharmacodynamic-based dosing calculator in critically ill patients","author":"Heil","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijantimicag.2026.107883_bib0005","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial","volume":"48","author":"Hagel","year":"2022","journal-title":"Intensive Care Med"},{"issue":"12","key":"10.1016\/j.ijantimicag.2026.107883_bib0006","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1007\/s00134-022-06921-9","article-title":"Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial","volume":"48","author":"Ewoldt","year":"2022","journal-title":"Intensive Care Med"},{"issue":"8","key":"10.1016\/j.ijantimicag.2026.107883_bib0007","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/jama.2024.9803","article-title":"Prolonged vs intermittent infusions of \u03b2-lactam antibiotics in adults with sepsis or Septic shock: a systematic review and meta-analysis","volume":"332","author":"Abdul-Aziz","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ijantimicag.2026.107883_bib0008","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.ijantimicag.2026.107883_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107192","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients \u2013 an international perspective on access, utilisation, and barriers","volume":"64","author":"Williams","year":"2024","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107883_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcrc.2009.02.014","article-title":"Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia","volume":"25","author":"Nicasio","year":"2010","journal-title":"J Crit Care"},{"issue":"2","key":"10.1016\/j.ijantimicag.2026.107883_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.10.018","article-title":"Antimicrobial dosing in critical care: a pragmatic adult dosing nomogram","volume":"55","author":"Williams","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.ijantimicag.2026.107883_bib0012","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jac\/dkae058","article-title":"What are the optimal pharmacokinetic\/pharmacodynamic targets for beta-lactamase inhibitors? A systematic review","volume":"79","author":"Assefa","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.ijantimicag.2026.107883_bib0013","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.ijantimicag.2026.107883_bib0014","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","article-title":"Beta-lactam Infusion in severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis","volume":"42","author":"Abdul-Aziz","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2026.107883_bib0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13054-015-0750-y","article-title":"Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?","volume":"19","author":"Udy","year":"2015","journal-title":"Crit Care"},{"issue":"11","key":"10.1016\/j.ijantimicag.2026.107883_bib0016","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/phar.2753","article-title":"In silico evaluation of a beta-lactam dosing guideline among adults with serious infections","volume":"43","author":"Williams","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107883_bib0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1378\/chest.11-1671","article-title":"Subtherapeutic initial \u03b2-lactam concentrations in select critically ill patients","volume":"142","author":"Udy","year":"2012","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ijantimicag.2026.107883_bib0018","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00134-024-07353-3","article-title":"Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsis","volume":"50","author":"Chai","year":"2024","journal-title":"Intensive Care Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926001706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926001706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:41:34Z","timestamp":1787438494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926001706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0924857926001706"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107883","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective evaluation of therapeutic target attainment with a beta-lactam dosing nomogram in critically ill adult patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107883"}}